JERSEY CITY, N.J., June 14, 2018 /PRNewswire/ -- SCYNEXIS, Inc.
(NASDAQ: SCYX), a biotechnology company developing innovative
therapies for difficult-to-treat and often life-threatening
infections, today announced one poster presentation at ICHS,
June 17-19, 2018, in Athens, Greece, one poster presentation at the
Teratology Society 58th Annual Meeting, June 23-27, 2018, in Clearwater, Florida and one poster
presentation at ISHAM, June 30- July 4,
2018, in Amsterdam, the
Netherlands. SCY-078, the first representative of a novel
oral and intravenous (IV) triterpenoid antifungal family, is in
clinical development for the treatment of multiple serious fungal
infections, including vulvovaginal candidiasis (VVC), invasive
candidiasis (IC), invasive aspergillosis (IA) and refractory
invasive fungal infections.
Meeting: 20th International Symposium on
Infections in the Immunocompromised Host (ICHS)
Title: SCY-078: A First-in-class, Orally-bioavailable,
Glucan Synthase Inhibitor has Activity Alone and is Synergistic
with Azole Antifungal Agents against Aspergillus spp.
Date/Time: Monday, June 18,
10:00-11:00 EEST and Tuesday, June 19, 10:00-11:00 EEST
Poster Presentation #: 14
Meeting: The Teratology Society 58th Annual
Meeting
Title: SCY-078, a Novel IV/Oral Triterpenoid Antifungal
Treatment, is Not Embryo/Feto-toxic
Date/Time: Tuesday, June 26,
6:00-7:30 PM ET
Poster Presentation #: 56
Meeting: 20th Congress of the International
Society for Human and Animal Mycology (ISHAM)
Title: SCY-078: A first-in-class, orally-bioavailable,
glucan synthase inhibitor has fungicidal activity against C.
auris, a multi-drug resistant emerging pathogen
Date/Time: Sunday, July 1,
6:14-6:21 PM CET
Poster Presentation #: PP2.091
All posters will be available on the SCYNEXIS website following
each event.
About SCY-078
SCY-078 is an investigational
antifungal agent that is a semi-synthetic derivative of the natural
product enfumafungin. SCY-078 is the first representative of a
novel class of structurally-distinct glucan synthase inhibitors,
triterpenoids. This agent combines the well-established activity of
glucan synthase inhibitors with the potential flexibility of having
oral and IV formulations. SCY-078 is currently in development for
the treatment of fungal infections caused primarily
by Candida (including C. auris)
and Aspergillus species. It has demonstrated broad
spectrum antifungal activity, in
vitro and in vivo, against multidrug-resistant
pathogens, including azole- and echinocandin-resistant strains.
The FDA has granted QIDP and Fast Track designations for
the formulations of SCY-078 for the indications of IC
(including candidemia), IA and VVC, and has granted Orphan
Drug Designation for the IC and IA indications.
About SCYNEXIS
SCYNEXIS, Inc. (NASDAQ: SCYX) is a
biotechnology company committed to positively impacting the lives
of patients suffering from difficult-to-treat and often
life-threatening infections by developing innovative therapies.
The SCYNEXIS team has extensive experience in the
life sciences industry, discovering and developing more than 30
innovative medicines over a broad range of therapeutic areas. The
Company's lead product candidate, SCY-078, is a novel IV/oral
antifungal agent in Phase 2 clinical and preclinical development
for the treatment of multiple serious and life-threatening invasive
fungal infections caused
by Candida and Aspergillus species.
For more information, visit www.scynexis.com.
Forward Looking Statement
Statements contained in this press release regarding expected
future events or results, including but not limited to the
Company's plans regarding clinical developments, are
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Because such statements
are subject to risks and uncertainties, actual results may differ
materially from those expressed or implied by such forward-looking
statements. These risks and uncertainties include, but are not
limited, to: risks inherent in SCYNEXIS's ability to
successfully develop and obtain FDA approval for SCY-078;
the expected costs of studies and when they might begin or be
concluded; and SCYNEXIS's reliance on third parties to
conduct SCYNEXIS's clinical studies. These and other
risks are described more fully in SCYNEXIS's filings with
the Securities and Exchange Commission, including without
limitation, its most recent Annual Report on Form 10-K under the
caption "Risk Factors" and other documents subsequently filed with
or furnished to the Securities and Exchange Commission. All
forward-looking statements contained in this press release speak
only as of the date on which they were
made. SCYNEXIS undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date on which they were made.
CONTACT:
Investor
Relations
Natalie
Wildenradt
Argot Partners
Tel: 212-600-1902
natalie@argotpartners.com
Media Relations
George E. MacDougall
MacDougall Biomedical Communications
Tel: 781-235-3093
george@macbiocom.com
View original
content:http://www.prnewswire.com/news-releases/scynexis-to-present-scy-078-data-at-three-scientific-meetings-in-junejuly-2018-300666123.html
SOURCE SCYNEXIS, Inc.